The American Diabetes Association (ADA) annually updates its Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes.
A therosclerotic cardiovascular disease (ASCVD), defined as coronary heart disease, cerebrovascular disease, or peripheral artery disease, is the leading cause of morbidity and mortality in persons with diabetes and is the largest contributor to the direct and indirect costs of diabetes. The 2018 American Diabetes Association (ADA) Standards of Medical Care recommend that cardiovascular risk factors be assessed at least annually in all patients with diabetes. This synopsis focuses on the ADA guidance relating to cardiovascular disease and risk management in nonpregnant adults with diabetes. Recommendations address diagnosis and treatment of cardiovascular risk factors (hypertension and dyslipidemia), aspirin use, screening for and treatment of coronary heart disease, and lifestyle interventions.
athy and therefore require adjustment of blood pressure targets.
Treatment Goal Recommendations
Most The ADA Standards of Medical Care emphasize individualization of blood pressure targets. Guidelines from other organizations (4) and large randomized trials (6 -10) clearly establish that treating patients with baseline systolic blood pressure of 140 mm Hg or greater to targets below this level is beneficial. More intensive targets may offer additional benefits for some patients but may also incur additional costs. Patients and clinicians should engage in a shared decisionmaking process to determine individual blood pressure targets (5) . Factors that may influence targets include risks of treatment (such as hypotension or drug adverse effects); life expectancy; comorbidities, including vascular and renal complications; patient attitude and expected treatment efforts; and resources and support system. In older adults, individualized blood pressure goals should minimize other risks, such as falls (11, 12) .
Lifestyle Intervention Recommendation For patients with blood pressure >120/80 mm Hg, lifestyle intervention consists of weight loss if overweight or obese; a Dietary Approaches to Stop Hypertensionstyle dietary pattern including reducing sodium and increasing potassium intake; moderation of alcohol intake; and increased physical activity. (Grade B recommendation)
Lifestyle intervention should be initiated along with pharmacologic therapy when hypertension is diagnosed (11). In patients with blood pressure greater than 120/80 mm Hg, lifestyle interventions include losing weight if the patient is overweight or obese; following the DASH (Dietary Approaches to Stop Hypertension) dietary pattern (13) , including restricting sodium intake (<2300 mg/d) and increasing intake of potassium, fruits and vegetables (8 to 10 servings per day), and low-fat dairy products (2 to 3 servings per day); avoiding excessive alcohol consumption; and increasing activity levels (11). Decreasing sodium intake to no more than 1500 mg/d may improve blood pressure in certain circumstances (14, 15), but restriction to this level for all patients with diabetes is not recommended (16, 17) .
Pharmacologic Intervention Recommendations
Patients Initial treatment for patients with diabetes depends on the severity of hypertension ( Figure 1 ). Several considerations might affect selection of the class of antihypertensive medication. Titration and/or addition of further blood pressure medications is important to avoid clinical inertia and to achieve and maintain blood pressure targets.
LIPID MANAGEMENT Lifestyle Intervention Recommendations
Lifestyle 
mmol/L] for women). (Grade C recommendation)
Patients should replace saturated fats with unsaturated fats rather than refined carbohydrates (18) . Ran-domized trials do not support use of n-3 fatty acid supplements for primary or secondary prevention of ASCVD (19 -23) . Randomized trials show that a Mediterranean-style diet rich in polyunsaturated and monounsaturated fats can improve glycemic control and lipid levels (18, 24 -29) .
Lipid Panel Monitoring Recommendations
In This figure can also be found in the American Diabetes Association position statement "Diabetes and Hypertension." ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; BP = blood pressure; CCB = calcium-channel blocker; UACR = urinary albumin-creatinine ratio. * An ACEi or ARB is suggested to treat hypertension for patients with UACR 30 -299 mg/g creatinine and strongly recommended for patients with UACR ≥300 mg/g creatinine. † Dihydropyridine calcium-channel blocker. ‡ Thiazide-like diuretic; long-acting agents shown to reduce cardiovascular events, such as chlorthalidone and indapamide, are preferred. Patients with type 2 diabetes have increased prevalence of lipid abnormalities, contributing to their high risk for ASCVD. The American College of Cardiology/ American Heart Association ASCVD risk calculator (www .cvriskcalculator.com) has limited use for assessing cardiovascular risk in persons with diabetes because it does not account for the duration of diabetes or the presence of other complications, such as albuminuria (30) .
CLINICAL GUIDELINE
Given that clinical trials show beneficial effects of statin therapy on ASCVD outcomes in patients with and without coronary heart disease (31, 32), statins are the drug of choice for LDL cholesterol lowering and cardioprotection. High-intensity statin therapy achieves a reduction of approximately 50% in LDL cholesterol level, and moderate-intensity regimens achieve reductions of 30% to 50%. Low-dose statin therapy is generally not recommended in patients with diabetes but is sometimes the only dose that a patient can tolerate.
For primary prevention in patients aged 40 to 75 years without clinical ASCVD, moderate-dose statin therapy is recommended (33) (34) (35) , although high-intensity therapy may be considered for certain patients with additional ASCVD risk factors. Few persons older than 75 years were enrolled in trials of statins; however, the absolute benefits of treatment for them may exceed the benefits for younger persons because increasing age generally confers higher risk for ASCVD (32) . Moderate-intensity statin therapy is recommended in patients with diabetes who are older than 75 years, with downward titration of the dose if needed on the basis of risk-benefit profile assessments.
Little evidence from clinical trials exists for patients with type 2 diabetes who are younger than 40 years and for those with type 1 diabetes of any age. Patients younger than 40 years have lower risk for cardiovascular events over a 10-year horizon; however, their lifetime risk for ASCVD and myocardial infarction, stroke, or cardiovascular death is high. For patients younger than 40 years with type 2 diabetes and other ASCVD risk factors and for patients with type 1 diabetes and other ASCVD risk factors, we recommend that the patient and the health care provider discuss relative benefits and risks and consider use of moderate-intensity statin therapy.
For secondary prevention in patients with ASCVD, high-intensity statin therapy is recommended (32, 36, 37) . Recent randomized trials investigating the benefits of adding nonstatin agents (ezetimibe [38] and PCSK9 inhibitors [39] ) to statin therapy showed reduced risk for ASCVD events with the added therapy that seemed to be related to the degree of further LDL cholesterol lowering. Ezetimibe is indicated to reduce LDL cholesterol levels in patients with hyperlipidemia, and the PCSK9 inhibitors evolocumab and alirocumab have been approved as adjunctive therapy for patients with ASCVD or familial hypercholesterolemia who are receiving maximum tolerated statin therapy but require additional lowering of LDL cholesterol levels (40, 41) .
Triglyceride Treatment Recommendation
For patients with fasting triglyceride levels ≥500 mg/dL (5.7 Combination therapy with a statin and a fibrate is associated with increased risk for abnormal aminotransferase levels, myositis, and rhabdomyolysis. In the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, the combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke compared with simvastatin alone (43) . Combination therapy with a statin and extended-release niacin was evaluated in a trial that was halted early due to lack of efficacy on the primary composite outcome (cardiac death, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome [ACS], or symptom-driven coronary or cerebral revascularization) and a possible increase in ischemic stroke in patients receiving combination therapy (44) .
Concerns About Statin Use
Several studies have shown that statin use is associated with a modestly increased risk for incident diabetes; the increased risk may be limited to persons with diabetes risk factors (45) (46) (47) . In one study, the absolute risk increase was small (1.2% of participants receiving placebo and 1.5% receiving rosuvastatin developed diabetes over 5 years of follow-up), and the cardiovascular event rate reduction with statins outweighed the risk
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CLINICAL GUIDELINE for diabetes, even for patients at the highest risk for diabetes (47) .
Concern that statins or other lipid-lowering agents might cause cognitive dysfunction or dementia should not preclude their use in patients with diabetes who are at high risk for ASCVD. A recent systematic review of the U.S. Food and Drug Administration's (FDA) postmarketing surveillance databases that evaluated cognition in patients receiving statins found that published data do not show an adverse effect of statins on cognition (48) . The benefit of aspirin for patients with no previous cardiovascular events is controversial (49, 50) . Some randomized trials in diabetic patients have had inconsistent findings or findings among women that differ from those in men (51) (52) (53) . A meta-analysis of 6 large primary prevention trials found that aspirin reduced the risk for serious vascular events by 12% (relative risk, 0.88 [95% CI, 0.82 to 0.94]) (49) . The largest reduction was for nonfatal myocardial infarction, with no statistically significant effect on coronary heart disease death (relative risk, 0.95 [CI, 0.78 to 1.15]) or total stroke. Aspirin reduced overall ASCVD events in men but not in women. Conversely, aspirin had no effect on stroke in men but reduced stroke in women. Of note, secondary prevention studies have not found differences in efficacy between sexes (49).
ANTIPLATELET AGENT RECOMMENDATIONS
Aspirin is not recommended for patients at low risk for ASCVD (men and women aged <50 years with diabetes and no other major ASCVD risk factors) because risks for bleeding likely outweigh possible benefits. Clinical judgment should be used for patients at intermediate risk (younger patients with ≥1 risk factor or older patients with no risk factors) until further outcomes research is conducted. Aspirin therapy in patients younger than 21 years is typically contraindicated because of the risk for Reye syndrome.
There is little evidence to support a specific aspirin dose, although expert opinion suggests that 75 to 162 mg/d is optimal (54) . Using the lowest possible dose may help reduce adverse effects (55) . The most common low-dose tablet in the United States is 81 mg.
The combination of a P2Y12 receptor antagonist and aspirin should be used for at least 1 year in patients who have had an ACS and may have benefits beyond this period. The strongest evidence supports use of clopidogrel or ticagrelor if percutaneous coronary intervention was not performed and clopidogrel, ticagrelor, or prasugrel if it was performed (56) . In patients with diabetes and prior myocardial infarction (1 to 3 years before), adding ticagrelor to aspirin significantly reduced risk for recurrent ischemic events, including coronary heart disease and cardiovascular death (57) .
CORONARY HEART DISEASE Screening Recommendations
In
asymptomatic patients, routine screening for coronary artery disease is not recommended as it does not improve outcomes as long as ASCVD risk factors are treated. (Grade A recommendation) Consider investigations for coronary artery disease in the presence of any of the following: atypical cardiac symptoms (e.g., unexplained dyspnea, chest discomfort); signs or symptoms of associated vascular disease including carotid bruits, transient ischemic attack, stroke, claudication, or peripheral arterial disease; or electrocardiogram abnormalities (e.g., Q waves). (Grade E recommendation)
Screening of asymptomatic patients with high ASCVD risk is not recommended (58), in part because high-risk patients should already be receiving intensive medical therapy-an approach that provides benefit similar to that of invasive revascularization (59, 60) . Studies have shown that a risk factor-based approach to the initial diagnostic evaluation and subsequent follow-up for coronary artery disease fails to identify which patients with type 2 diabetes will have silent ischemia on screening tests (61, 62) . Any benefit of newer noninvasive screening methods for coronary artery disease, such as computed tomography and computed tomography angiography, to identify patient subgroups for different treatment strategies remains unproven.
Pharmacologic Treatment Recommendations
In 
CLINICAL GUIDELINE Review of the ADA Standards of Medical Care in Diabetes 2018 cardiovascular events and cardiovascular mortality (currently empagliflozin and liraglutide), after considering drug-specific and patient factors (see Figure 2). (Grade A recommendation) In patients with type 2 diabetes and established ASCVD, after lifestyle management and metformin, the antihyperglycemic agent canagliflozin may be considered to reduce major adverse cardiovascular events based on drug-specific and patient factors (see Figure 2). (Grade C recommendation)
Patients at increased ASCVD risk should receive aspirin, a statin, and an ACE inhibitor or angiotensinreceptor blocker if they have hypertension unless a particular drug class is contraindicated. Although clear benefit exists for ACE inhibitor or angiotensin-receptor blocker therapy in patients with diabetic kidney disease or hypertension, the benefits in patients with ASCVD in the absence of these conditions are less clear, especially when LDL cholesterol is concomitantly controlled (63, 64) . In patients with prior myocardial infarction, active angina, or heart failure, ␤-blockers should be used (65) . Figure 2 summarizes aspects of glucose-lowering agents, including cardiovascular effects, costs, and FDA black box warnings. The Table shows recent cardiovascular outcomes trials that provide relevant data about newer medications for patients with type 2 diabetes who have or are at high risk for cardiovascular disease. Most trials were randomized placebo-controlled trials that examined newer drugs in combination with metformin (unless it was contraindicated or not tolerated). Trials of new agents have had mixed results; empagliflozin, liraglutide, and canagliflozin had the strongest evidence of benefit. In the EMPA-REG OUTCOME trial, ‡ Age was reported as means in all trials except EXAMINE, which reported medians; diabetes duration was reported as means in all but four trials, with SAVOR-TIMI 53, EXAMINE, and EXSCEL reporting medians and EMPA-REG OUTCOME reporting as percentage of population with diabetes duration >10 years. § Significant difference in A1C between groups (P < 0.05). ͉͉ A1C change of 0.66% with 0.5 mg and 1.05% with 1 mg dose of semaglutide. ¶ A1C change of 0.30 in EMPA-REG OUTCOME is based on pooled results for both doses (i.e., 0.24% for 10 mg and 0.36% for 25 mg of empagliflozin). ** Outcomes reported as HR (95% CI).
† † On the basis of prespecified outcomes, the renal outcomes are not viewed as statistically significant. ‡ ‡ Truncated data set (prespecified in treating hierarchy as the principal data set for analysis for superiority of all-cause mortality and cardiovascular death in the CANVAS Program). § § Nontruncated data set. ͉͉͉͉ Truncated integrated data set (refers to pooled data from CANVAS after 20 November 2012 plus CANVAS-R; prespecified in treating hierarchy as the principal data set for analysis for superiority of all-cause mortality and cardiovascular death in the CANVAS Program). ¶ ¶ Nontruncated integrated data (refers to pooled data from CANVAS, including before 20 November 2012 plus CANVAS-R). *** Worsening nephropathy is defined as the new onset of UACR >300 mg/g creatinine or a doubling of the serum creatinine level and an estimated glomerular filtration rate of <45 mL/min/1.73 m 2 , the need for continuous renal-replacement therapy, or death from renal disease in EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 and as doubling of creatinine level, initiation of dialysis, renal transplantation, or creatinine >6.0 mg/dL (530 μmol/L) in SAVOR-TIMI 53. Worsening nephropathy was a prespecified exploratory adjudicated outcome in SAVOR-TIMI 53, LEADER, and SUSTAIN-6 but not in EMPA-REG OUTCOME.
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empagliflozin reduced the composite outcome of myocardial infarction, stroke, and cardiovascular death by 14% and cardiovascular death by 38% (66) . The FDA recently added a new indication for empagliflozin to reduce the risk for cardiovascular death in adults with type 2 diabetes and cardiovascular disease. In the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial, the primary composite outcome (myocardial infarction, stroke, or cardiovascular death) occurred in fewer participants in the liraglutide group than the placebo group (13% vs. 14.9%) (67). Deaths due to cardiovascular causes were also reduced in the liraglutide group (4.7%) compared with the placebo group (6.0%) (67). The FDA recently approved use of liraglutide to reduce risk for major adverse cardiovascular events, myocardial infarction, stroke, and cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. The combined results from CANVAS (Canagliflozin Cardiovascular Assessment Study) and the CANVAS renal end points trial (CANVAS-R) found that, compared with placebo, canagliflozin reduced the composite outcome of cardiovascular death, myocardial infarction, or stroke (68) . The observed reduction for cardiovascular death alone was not statistically significant (hazard ratio, 0.87 [CI, 0.72 to 1.06]) (68).
LIFESTYLE INTERVENTIONS
Lifestyle interventions, including weight loss, increased physical activity, medical nutrition therapy, and smoking cessation, may beneficially modify ASCVD risk factors in some patients. Intensive lifestyle intervention focusing on weight loss through decreased caloric intake and increased physical activity as performed in the Look AHEAD (Action for Health in Diabetes) trial may improve glucose control, fitness, and some ASCVD risk factors (69) . In obese persons with type 2 diabetes, weight loss greater than 5% is needed to produce beneficial outcomes in glycemic control, lipids, and blood pressure, and sustained weight loss greater than 7% is optimal (70) .
Smokers with diabetes and persons with diabetes who are exposed to secondhand smoke have heightened risk for ASCVD as well as premature death and microvascular complications. Routine and thorough assessment of tobacco use is essential to prevent smoking or encourage cessation. 
